 Affimeds wholly-owned pipeline programs continue to report impressive clinical data that supports a long-term investment. I believe is Affimed is trailblazing on a new approach in oncology. The companys three-pronged approach of testing their products as a monotherapy, NK combo, and I-O combo, has revealed impressive results. 